Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pazopanib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A: Pazopanib with Radium-223 | EXPERIMENTAL | No prior targeted therapy * Pazopanib oral, daily and at predetermined dosage per cycle * Radium-223 predetermined dosage via IV, per cycle |
| Arm B: Sorafenib with Radium-223 | EXPERIMENTAL | At least one line of prior targeted therapy: * Sorafenib at predetermined dosage, mouth twice daily * Radium-223 predetermined dosage via IV, per cycle |
| Name | Type | Description |
|---|---|---|
| Pazopanib | DRUG | - |
| Sorafenib | DRUG | - |
| Radium-223 | DRUG | - |
Inclusion Criteria: * Age ≥ 18 years. * Documented pathologic diagnosis of RCC. All subtypes eligible including but not limited to clear cell, papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, and unclassified categories. Sarcomatoid and rhabdoid differentiation are allowed. *...
Pazopanib is an investigational small molecule being studied for the treatment of metastatic renal cell carcinoma. It is currently in Phase 1 clinical development. The drug is being evaluated in a completed clinical trial that enrolled 30 patients with this condition.
Pazopanib is being developed by Bayer AG, a company traded under the ticker BAYRY. The drug is currently in Phase 1 clinical development for metastatic renal cell carcinoma.
Pazopanib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of metastatic renal cell carcinoma.
Pazopanib has one completed clinical trial with the identifier NCT02406521. This Phase 1 study, titled 'Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets,' enrolled 30 patients in the United States.
Pazopanib is not known to have any alternative names. It is being developed by Bayer AG under this name for the treatment of metastatic renal cell carcinoma.